The trial is designed to assess the efficacy of DanDrit’s vaccine MelCancerVac (MCV) in stage IV CRC patients rendered disease free after the completion of standard treatments in accordance with local practices.
San Martino Hospital head of the Medical Oncology Unit Dr Alberto Sobrero is the principal investigator of the randomized multicenter trial.
DanDrit chief executive officer Dr Eric Leire said over the last year the company has focused its efforts on developing MCV for colorectal cancer patients.
"We intend to continue our efforts to develop a vaccine that we hope can ameliorate the scourge of colorectal cancer," Leire said.
DanDrit Biotech is a subsidiary of DanDrit Biotech USA, a biotechnology firm seeking to develop an approved vaccine for the treatment of colorectal cancer.